ORBIMED ADVISORS LLC 13D/13G Filings for Keros Therapeutics, Inc. (KROS)

ORBIMED ADVISORS LLC 13D and 13G filings for Keros Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime		Transaction
Date		TypeCompany
Symbol		Filed By
Symbol		Shares Owned
% Owned		Shares Vs. Prev ReportView
2023-12-13
5:20 pm
Unchanged		2023-12-1113DKeros Therapeutics, Inc.
KROS		ORBIMED ADVISORS LLC1,268,734
4.200%		0
(Unchanged)		Filing
2022-11-07
4:25 pm
Unchanged		2022-11-0313DKeros Therapeutics, Inc.
KROS		ORBIMED ADVISORS LLC1,268,734
4.600%		0
(Unchanged)		Filing
2020-11-20
4:32 pm
Unchanged		2020-11-1913DKeros Therapeutics, Inc.
KROS		ORBIMED ADVISORS LLC1,268,734
5.500%		0
(Unchanged)		Filing
2020-04-17
4:07 pm
Purchase		2020-04-0813DKeros Therapeutics, Inc.
KROS		ORBIMED ADVISORS LLC1,268,734
6.300%		1,268,734increase
(New Position)		Filing